FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Orphan Status for Mabwell Esophageal Cancer Drug

FDA grants China-based Mabwell an orphan drug designation for its novel Nectin-4-targeting antibody-drug conjugate 9MW2821 for treating esophageal can...

latest-news-card-1
Human Drugs

Tandem Diabetes Recalls Pump Mobile App

Tandem Diabetes Care recalls its t:connect mobile app (version 2.7) on the Apple iOS platform that is used with the companys t:slim X2 insulin pump.

latest-news-card-1
Federal Register

Party Drug MDMA Goes to Panel for PTSD

Federal Register notice: FDA announces a 6/4 Psychopharmacologic Drugs Advisory Committee meeting to discuss a Lykos Therapeutics NDA for midomafetami...

latest-news-card-1
Biologics

Marks OK with Some Gene Accelerated Approval Mistakes

CBER director Peter Marks says FDA is working to achieve 90% correct decisions on gene therapy accelerated approvals.

latest-news-card-1
Human Drugs

Latest Implied Preemption Case Reviewed

Three Winston & Strawn attorneys say that by declining to hear an appeal, the Supreme Court has affirmed that some state law claims may be preempted b...

latest-news-card-1
Medical Devices

Multiple Violations in Bioptimal Inspection

FDA warns Chinas Bioptimal International about multiple violations at a Singapore facility manufacturing two unapproved catheters.

latest-news-card-1
Medical Devices

CDRH Product Evaluation/Quality Office Modified

Federal Register notice: FDA announces that CDRH Office of Product Evaluation and Quality has modified its organizational structure.

latest-news-card-1
Human Drugs

FDA OKs TE Code for Paclitaxel Suspension

FDA approves an AB therapeutic equivalence code for cancer drug paclitaxel suspension and tells HBT Labs it must formally apply for a return of PDUFA ...

latest-news-card-1
Human Drugs

Bioresearch Monitoring Violations at DBC Research

FDA warns Dr. Kevin Bender, doing business as DBC Research in Tamarac, FL, about violations in his conduct of clinical trials.

latest-news-card-1
Human Drugs

Endo Paying $1.5 Billion Fines, Forfeitures

Endo is ordered to pay $1.85 billion in fines and forfeitures after pleading guilty to introducing misbranded Opana ER into interstate commerce and cl...